Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL3549 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29357903 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL28131624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL3550 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5535862 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29594152 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29554704 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL6340124 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL29879166 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNATUBB4A | |
| Vinblastine SCHEMBL5306718 | 0.99 | MAPT (0.99) | MAPTMEN1KMT2ALMNATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260048141-A1 | NANOPARTICLES COMPRISING A FUNCTIONAL AGENT AND METHOD OF PREPARATION AND USE THEREOF | YUAN YUMIN (CN) | 2026-02-19 | — | — | US | disclosed |
| US-12409234-B1 | Nanoparticles comprising a functional agent and method of preparation and use thereof | SINOPEG LIMITED (HK) | 2025-09-09 | — | — | US | disclosed |
| CN-117919245-A | Application of vinblastine in preparation of antitumor immunotherapeutic medicine | 上海交通大学医学院 | 2024-04-26 | — | — | CN | disclosed |
| CN-112480148-B | Synthesis method of vinblastine sulfate | 海南长春花药业有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20190345536-A1 | DETECTION METHOD FOR CHROMOSOMAL ABNORMALITIES AND METHOD FOR EVALUATING INDUCIBILITY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-11-14 | — | — | US | disclosed |
| US-10000793-B2 | Method for enumeration of mammalian cell micronuclei, while distinguishing chromatin of dead and dying cells | LITRON LABORATORIES, LTD. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-1769081-B1 | METHOD FOR ENUMERATING MAMMALIAN CELL MICRONUCLEI WITH AN EMPHASIS ON DIFFERENTIALLY STAINING MICRONUCLEI AND THE CHROMATIN OF DEAD AND DYING CELLS | LITRON LAB LTD (US) | 2016-01-20 | — | — | EP | disclosed |
| US-7745152-B2 | Method for determining genotoxicity | ROCHE PALO ALTO LLC (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100112594-A1 | METHOD FOR ENUMERATING MAMMALIAN CELL MICRONUCLEI WITH AN EMPHASIS ON DIFFERENTIALLY STAINING MICRONUCLEI AND THE CHROMATIN OF DEAD AND DYING CELLS | LITRON LABORATORIES, LTD. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7645593-B2 | Contacting with fluorescent DNA dye, lysis solution that digests outer membranes, RNAse; detecting fluorescent emission and light scatter; assess DNA-damaging potential of chemical agent | LITRON LABORATORIES, LTD. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| US-20090029386-A1 | KIT FOR ENUMERATING MAMMALIAN CELL MICRONUCLEI WITH AN EMPHASIS ON DIFFERENTIALLY STAINING MICRONUCLEI AND THE CHROMATIN OF DEAD AND DYING CELLS | LITRON LABORATORIES, LTD. (US) | 2009-01-29 | — | — | US | disclosed |
| US-7445910-B2 | Method for enumerating mammalian cell micronuclei with an emphasis on differentially staining micronuclei and the chromatin of dead and dying cells | LITRON LABORATORIES, LTD. (US) | 2008-11-04 | — | — | US | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| CN-101065501-A | Method for determining genotoxicity | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | CN | disclosed |
| US-20060110768-A1 | Method for determining genotoxicity | ROCHE PALO ALTO LLC | 2006-05-25 | — | — | US | disclosed |
| US-20060040291-A1 | Method for enumerating mammalian cell micronuclei with an emphasis on differentially staining micronuclei and the chromatin of dead and dying cells | LITRON LABORATORIES, LTD. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409234-B1 | Nanoparticles comprising a functional agent and method of preparation and use thereof | LITAF, MYD88, CD47 | TUBB4A 3081/4885TUBB 3700/4885TUBA3C 2807/4885 |
| US-20260048141-A1 | NANOPARTICLES COMPRISING A FUNCTIONAL AGENT AND METHOD OF PREPARATION AND USE THEREOF | TP53, CD47, MYD88 | TUBB4A 3513/4885TUBB 3675/4885TUBA3C 3562/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | TUBB4A 384/4885TUBB 571/4885TUBA3C 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.